US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Genomics Immunology and Healthcare ETF

40.42

-0.4600-1.13%

Pre-market: 40.420.00000.00%07:38 EDT

Volume:85.59K

Turnover:3.43M

Market Cap:301.13M

PE:- -

High:40.43

Open:40.36

Low:39.72

Close:40.88

52wk High:43.44

52wk Low:23.90

Shares:7.45M

Float Shares:7.45M

Volume Ratio:0.47

T/O Rate:1.15%

Dividend:0.28

Dividend Rate:0.70%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Incyte (INCY) Receives a Buy from Bank of America Securities

GH Research to Present TRD and Bipolar Trial Data at ECNP 2026

Teva announces FDA approval for Weltruza

Glaukos announces Phase 4 trial of iDose TR met primary efficacy endpoint

Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference

X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders

Learn Why The Bull Case For Moderna Stock Could Change Following COO Appointment

Simply Wall St.

Is Rare Disease Approval Altering The Investment Case For Incyte (INCY)?

Simply Wall St.

Everest Medicines Appoints Ex-Moderna Executive Lakshmi Srinivasan as Head of Translational Medicine

RBC Capital Remains a Hold on Moderna (MRNA)

Vertex to Raise Up to C$7 Million in Subordinated Loan with Attached Warrants

Press Release: Vertex Resource GROUP LTD. Announces Subordinated TERM LOAN of up to C$7,000,000

Xortx Therapeutics outlines anticipated clinical trial application for XRx-026

RBC would be buyers of Revolution Medicines after FDA docs ‘overreaction’

Revolution Medicines selloff ‘overdone and misguided,’ says TD Cowen

Revolution Medicines Falls on Pancreatic Cancer Drug Data Concerns

Revolution trading down after daraxonrasib review docs, says Stifel

Cboe data shows mixed options sentiment in Moderna with shares down 0.56%

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026

Incyte Updates Financial Calendar with Third-Quarter Results Conference Call and Webcast Schedule

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/IDNA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IDNA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","market":"US","secType":"STK","nameCN":"iShares Genomics Immunology and Healthcare ETF","latestPrice":40.42,"timestamp":1791489600000,"preClose":40.88,"halted":0,"volume":85591,"hourTrading":{"tag":"盘前","latestPrice":40.42,"preClose":40.42,"latestTime":"07:38 EDT","volume":3,"amount":121.22320199999999,"timestamp":1791545933537,"change":0,"changeRate":0,"amplitude":0.000495},"delay":0,"changeRate":-0.011252446183953053,"floatShares":7450000,"shares":7450000,"eps":0,"marketStatus":"Pre-Mkt","change":-0.46,"latestTime":"10-09 09:18:17 EDT","open":40.36,"high":40.43,"low":39.72,"amount":3429583.43904,"amplitude":0.017368,"askPrice":53.54,"askSize":100,"bidPrice":28,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791552600000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":40.42,"sharesOutstanding":5100000,"nav":40.752915,"aum":307684508.25,"dividendRate":0.006977,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":40.42,"preClose":40.42,"latestTime":"07:38 EDT","volume":3,"amount":121.22320199999999,"timestamp":1791545933537,"change":0,"changeRate":0,"amplitude":0.000495},"postHourTrading":{"tag":"盘后","latestPrice":40.42,"preClose":40.42,"latestTime":"19:56 EDT","volume":5346,"amount":216103.66,"timestamp":1791503775220,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.4660522394556619,"impliedVol":0.1441,"impliedVolPercentile":0.34},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","floatShares":7450000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.4660522394556619,"shares":7450000,"dividePrice":0.282,"high":40.43,"amplitude":0.017368,"preClose":40.88,"low":39.72,"week52Low":23.9,"pbRate":"--","week52High":43.44,"institutionHeld":0,"latestPrice":40.42,"eps":0,"divideRate":0.006977,"volume":85591,"delay":0,"ttmEps":0,"open":40.36,"prevYearClose":26.19,"prevWeekClose":41.65,"prevMonthClose":42.32,"prevQuarterClose":42.32,"fiveDayClose":41.64,"twentyDayClose":37.88,"sixtyDayClose":33.12},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IDNA\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"IDNA","amount":0.125421,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2025-12-16","symbol":"IDNA","amount":0.155456,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-06-16","symbol":"IDNA","amount":0.152909,"announcedDate":"2025-06-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-16","defaultRemindTime":1750080600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-20","payableDate":"2025-06-16","currency":"USD","dateTimestamp":1750046400000,"payDate":"2025-06-20"},{"date":"2024-12-17","symbol":"IDNA","amount":0.11105,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2024-06-11","symbol":"IDNA","amount":0.11144,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-11","defaultRemindTime":1718112600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-17","payableDate":"2024-06-11","currency":"USD","dateTimestamp":1718078400000,"payDate":"2024-06-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IDNA\",market:\"US\",,,undefined,":[{"executeDate":"2019-12-16","recordDate":"2019-12-17","paymentDate":"2019-12-20","value":0.237063,"currency":"USD"},{"executeDate":"2020-06-15","recordDate":"2020-06-16","paymentDate":"2020-06-19","value":0.083667,"currency":"USD"},{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-18","value":0.036209,"currency":"USD"},{"executeDate":"2021-06-10","recordDate":"2021-06-11","paymentDate":"2021-06-16","value":0.052145,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-17","value":0.256358,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IDNA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IDNA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2674851234","title":"Incyte (INCY) Receives a Buy from Bank of America Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2674851234","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674851234?lang=en_us&edition=fundamental","pubTime":"2026-10-09 20:16","pubTimestamp":1791548186,"startTime":"0","endTime":"0","summary":"Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on Incyte today and set a price target of $140.00. According to TipRanks, A...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/incyte-incy-receives-a-buy-from-bank-of-america-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/incyte-incy-receives-a-buy-from-bank-of-america-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0070302665.USD","BK4588","LU0208291251.USD","IE00B19Z3B42.SGD","TFNS","LU1880398471.USD","LU1894683348.USD","LU0211331839.USD","UYG","BK4585","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","IYG","LU0971096721.USD","BAC","LU0130517989.USD","LU0149725797.USD","LU2133065610.SGD","LU0106831901.USD","LU1035773651.USD","LU1894683264.USD","LU1162221912.USD","LU0648000940.SGD","PGF","BK4581","LU0130518102.USD","XLF","INCY","LU1291159041.SGD","LU1718418525.SGD","LU1989771016.USD","KBWB","IDNA","VFH","LU0256863811.USD","IE0002270589.USD","LU0320765489.SGD","LU0310800965.SGD","LU0234570918.USD","FNCL","LU0321505868.SGD","IYF","FTXO","LU0320765646.SGD","LU1074936037.SGD","LU1267930227.SGD","LU1804176565.USD","IE00BFXG1179.USD","LU2129689605.HKD","LU1506573853.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674785960","title":"GH Research to Present TRD and Bipolar Trial Data at ECNP 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2674785960","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674785960?lang=en_us&edition=fundamental","pubTime":"2026-10-09 19:27","pubTimestamp":1791545234,"startTime":"0","endTime":"0","summary":"GH Research ( ($GHRS) ) has issued an announcement. GH Research PLC announced that data from its GH001-TRD-201 and GH001-BD-202 clinical trials wil...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gh-research-to-present-trd-and-bipolar-trial-data-at-ecnp-2026?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gh-research-to-present-trd-and-bipolar-trial-data-at-ecnp-2026?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","GDOC","IDNA","HYLG","BMED","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674785642","title":"Teva announces FDA approval for Weltruza","url":"https://stock-news.laohu8.com/highlight/detail?id=2674785642","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674785642?lang=en_us&edition=fundamental","pubTime":"2026-10-09 19:05","pubTimestamp":1791543924,"startTime":"0","endTime":"0","summary":"Teva (TEVA) announced that the FDA has approved Weltruza for extended-release injectable suspension, a new, once-monthly, subcutaneous long-acting ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-for-weltruza-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-for-weltruza-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSCH","LFSC","TEVA","MRNY","GDOC","BK4588","BK4566","BK4007","IYH","XLVX","BBP","BK4596","IDNA","MEDI","TECB","BMED","LABU","NVIB","BK4557","IBB","LU2324357040.USD","FRTY","BK4584","IEIH","SYNB","GNMX","TBXU","RSPH","LU1983299246.USD","PINK","BK4559","BK4585","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674985629","title":"Glaukos announces Phase 4 trial of iDose TR met primary efficacy endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2674985629","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674985629?lang=en_us&edition=fundamental","pubTime":"2026-10-09 19:05","pubTimestamp":1791543914,"startTime":"0","endTime":"0","summary":"Glaukos (GKOS) announced topline results from the Phase 4 prospective, randomized, controlled clinical trial evaluating iDose TR administered in co...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/glaukos-announces-phase-4-trial-of-idose-tr-met-primary-efficacy-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/glaukos-announces-phase-4-trial-of-idose-tr-met-primary-efficacy-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","IDNA","HYLG","IE0009354923.USD","LU2065731478.USD","LU1878469433.USD","GDOC","BK4082","NVIB","GKOS","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674856429","title":"Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2674856429","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674856429?lang=en_us&edition=fundamental","pubTime":"2026-10-09 19:00","pubTimestamp":1791543600,"startTime":"0","endTime":"0","summary":"Denifanstat showed continued improvement and sustained efficacy across all efficacy endpoints through 52 weeks, including 57% IGA success, 72% reduction in total lesions, and 77% reduction in inflamma","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/09/3377993/0/en/sagimet-to-present-positive-full-52-week-results-from-license-partner-ascletis-phase-3-open-label-extension-clinical-trial-of-denifanstat-in-acne-and-mechanistic-data-at-the-2026-f.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","HYLG","IDNA","MEDX","IGA","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674856405","title":"X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders","url":"https://stock-news.laohu8.com/highlight/detail?id=2674856405","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674856405?lang=en_us&edition=fundamental","pubTime":"2026-10-09 19:00","pubTimestamp":1791543600,"startTime":"0","endTime":"0","summary":"BOSTON, Oct.  09, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the Company will ho","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/09/3377996/0/en/x4-pharmaceuticals-to-host-virtual-investor-day-on-thursday-october-29-2026-featuring-key-opinion-leaders.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","MEDX","IDNA","BK4109","KEM","GDOC","HYLG","ASH","LU2463526074.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674859163","title":"Learn Why The Bull Case For Moderna Stock Could Change Following COO Appointment","url":"https://stock-news.laohu8.com/highlight/detail?id=2674859163","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674859163?lang=en_us&edition=fundamental","pubTime":"2026-10-09 18:44","pubTimestamp":1791542690,"startTime":"0","endTime":"0","summary":"Moderna appointed former executive Juan Andres as Chief Operating Officer in early October 2026, tasking him with overseeing global manufacturing and operational execution as the firm scales beyond its COVID-19 vaccine and advances its oncology portfolio, including intismeran autogene.\nThe return of Andres, who previously led Moderna’s large-scale manufacturing build-out and quality operations, signals management emphasis on execution discipline and capacity readiness as the business...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/128680956-card/1789197794273","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/128680956-card/1789197794273"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrna/moderna/news/learn-why-the-bull-case-for-moderna-stock-could-change-follo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrna/moderna/news/learn-why-the-bull-case-for-moderna-stock-could-change-follo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4533","BK4501","BK4568","BK4534","BK4548","BK4585","WDNA","BK4588","LGHT","MRNA","MRNX","GNOM","BK4551","IDNA","EES","BK4532","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674383198","title":"Is Rare Disease Approval Altering The Investment Case For Incyte (INCY)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2674383198","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674383198?lang=en_us&edition=fundamental","pubTime":"2026-10-09 10:36","pubTimestamp":1791513417,"startTime":"0","endTime":"0","summary":"Incyte and Mirum Pharmaceuticals reported that the U.S. FDA previously approved Atebrioz (zilurgisertib), an oral ALK2 inhibitor for Fibrodysplasia Ossificans Progressiva in patients aged 12 and older, and granted Incyte a Rare Pediatric Disease Priority Review Voucher.\nThe approval of Atebrioz adds a rare disease product and a transferable FDA voucher to Incyte’s toolkit. This development could influence how the business funds and prioritizes its planned shift toward a broader,...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-incy/incyte/news/is-rare-disease-approval-altering-the-investment-case-for-in","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-incy/incyte/news/is-rare-disease-approval-altering-the-investment-case-for-in","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","INCY","BK4585","IDNA","BK4532","BK4139","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674049884","title":"Everest Medicines Appoints Ex-Moderna Executive Lakshmi Srinivasan as Head of Translational Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2674049884","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674049884?lang=en_us&edition=fundamental","pubTime":"2026-10-09 10:13","pubTimestamp":1791512025,"startTime":"0","endTime":"0","summary":"Everest Medicines appoints ex-Moderna executive Lakshmi Srinivasan as head of translational medicineEverest Medicines appointed Lakshmi Srinivasan as senior vice president, head of translational medic","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nNDL9xdVL5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","GNOM","MRNX","BK4568","BK4551","BK1161","MRNY","BK4534","WDNA","BK1574","BK4548","BK4532","BK4501","01952","BK1583","LGHT","MRNA","BK4585","IDNA","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674882317","title":"RBC Capital Remains a Hold on Moderna (MRNA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2674882317","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674882317?lang=en_us&edition=fundamental","pubTime":"2026-10-09 09:47","pubTimestamp":1791510478,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Luca Issi maintained a Hold rating on Moderna yesterday and set a price target of $130.00. According to TipRanks, Issi is an an...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-hold-on-moderna-mrna-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-hold-on-moderna-mrna-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","BK4551","LU0128525929.USD","GNOM","BK4139","BK4207","BK4568","IDNA","LU0708994859.HKD","LU1267930573.SGD","LU0029864427.USD","LU0310800379.SGD","BK4534","BK4588","GSIB","MRNA","BK4585","BK4533","LGHT","WDNA","BK4532","BK4501","MRNX","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674886821","title":"Vertex to Raise Up to C$7 Million in Subordinated Loan with Attached Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2674886821","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674886821?lang=en_us&edition=fundamental","pubTime":"2026-10-09 07:38","pubTimestamp":1791502698,"startTime":"0","endTime":"0","summary":"An update from Vertex Resource Group Ltd. ( ($TSE:VTX) ) is now available. Vertex Resource Group Ltd., a North American environmental services firm...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vertex-to-raise-up-to-c7-million-in-subordinated-loan-with-attached-warrants?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vertex-to-raise-up-to-c7-million-in-subordinated-loan-with-attached-warrants?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1035775433.USD","LU0432979614.USD","BK4585","IE00BJT1NW94.SGD","LU1093756168.USD","SG9999001176.USD","LU1674673428.USD","LU2362541513.USD","IE00B19Z9P08.USD","IE00B19Z3581.USD","LU2362541273.HKD","IBBQ","LU1778281490.HKD","BIB","LU0256863811.USD","LU0757428866.USD","LU1430594728.SGD","TBXU","LU0823416689.USD","LU2417539215.USD","BK4532","VRTX","IDNA","IE00B894F039.SGD","LU2237438978.USD","BBH","BK4567","IE00B19Z3B42.SGD","PBE","IE00B4R5TH58.HKD","LU1815336091.USD","LU0058720904.USD","LU0417517546.SGD","IE00B2B36J28.USD","LU1559883803.SGD","SGXZ57979304.SGD","GNMX","SG9999013999.USD","LU2089984988.USD","BK4588","LU2462157665.USD","LU2456880835.USD","BK4139","IE0009355771.USD","IBB","VERX","IE0002141913.USD","LU0061475181.USD","LU0566484027.USD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674883067","title":"Press Release: Vertex Resource GROUP LTD. Announces Subordinated TERM LOAN of up to C$7,000,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2674883067","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674883067?lang=en_us&edition=fundamental","pubTime":"2026-10-09 06:30","pubTimestamp":1791498600,"startTime":"0","endTime":"0","summary":"SHERWOOD PARK, AB, Oct. 8, 2026 /CNW/ -- (TSXV: VTX) -- Vertex Resource Group Ltd. (\"Vertex\" or the \"Corporation\") announces its intention to enter into a subordinated credit arrangement with Factory ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0432979614.USD","LU1674673691.USD","LU1674673428.USD","IBBQ","IE00B4R5TH58.HKD","SG9999001176.SGD","91013","BBH","IE00B19Z9Z06.USD","LU2462157665.USD","LU0889565916.HKD","VRTX","LU0061475181.USD","BK4567","LU1093756325.SGD","LU2362540622.SGD","IDNA","IE00BJT1NW94.SGD","LU2237438978.USD","IE0002141913.USD","BK4585","LU0289739699.SGD","BK4533","LU1778281490.HKD","LU2417539215.USD","VERX","PBE","BK4588","LU0079474960.USD","LU2362541273.HKD","SG9999001176.USD","TBXU","91512","IE0009355771.USD","LU0320765992.SGD","LU1585245621.USD","SGXZ57979304.SGD","IE00B894F039.SGD","IE0002270589.USD","GNMX","BIB","IBB","BK4139","LU0757428866.USD","LU2468319806.SGD","SG9999013999.USD","IE00BZ9MQY76.HKD","LU0109394709.USD","LU2456880835.USD","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674000503","title":"Xortx Therapeutics outlines anticipated clinical trial application for XRx-026","url":"https://stock-news.laohu8.com/highlight/detail?id=2674000503","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674000503?lang=en_us&edition=fundamental","pubTime":"2026-10-09 04:05","pubTimestamp":1791489913,"startTime":"0","endTime":"0","summary":"Xortx Therapeutics (XRTX) provided an outline of its anticipated clinical trial application, or CTA, submission to Health Canada for the XRx-026 go...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xortx-therapeutics-outlines-anticipated-clinical-trial-application-for-xrx-026-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xortx-therapeutics-outlines-anticipated-clinical-trial-application-for-xrx-026-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","HYLG","IDNA","MEDX","GDOC","CTA","NVIB","JPFP","DBMF","SDMF","BK4139","ISMF","LENZ","XRTX","TFPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674074190","title":"RBC would be buyers of Revolution Medicines after FDA docs ‘overreaction’","url":"https://stock-news.laohu8.com/highlight/detail?id=2674074190","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674074190?lang=en_us&edition=fundamental","pubTime":"2026-10-09 03:45","pubTimestamp":1791488724,"startTime":"0","endTime":"0","summary":"RBC Capital notes Revolution Medicines (RVMD) looks to be down in response to yesterday’s disclosure of FDA’s Rasonque review documents, particular...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rbc-would-be-buyers-of-revolution-medicines-after-fda-docs-overreaction-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rbc-would-be-buyers-of-revolution-medicines-after-fda-docs-overreaction-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBH","IE0009355771.USD","IE00B4R5TH58.HKD","GSIB","LABU","LU0889565916.HKD","IE00BJJMRZ35.SGD","IE0002141913.USD","LU0310800379.SGD","LU0708994859.HKD","BK4139","LU0109394709.USD","LU0029864427.USD","PTH","IE00BJT1NW94.SGD","RVMD","IE0009354923.USD","LU0320765992.SGD","BK4588","IDNA","IE00B2B36J28.USD","LU0128525929.USD","BK4207","BK4585","LU1267930573.SGD","CANC","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674077820","title":"Revolution Medicines selloff ‘overdone and misguided,’ says TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2674077820","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674077820?lang=en_us&edition=fundamental","pubTime":"2026-10-09 03:40","pubTimestamp":1791488425,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren reiterated a Buy rating on Revolution Medicines (RVMD), saying Thursday’s selloff on Rasonque’s reported efficacy ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-selloff-overdone-and-misguided-says-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-selloff-overdone-and-misguided-says-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0002141913.USD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","COWN","BBH","LU0109394709.USD","IE0009354923.USD","BK4127","IE00B2B36J28.USD","IDNA","IE00BFTCPJ56.SGD","CANC","LU0320765992.SGD","LU0889565916.HKD","PTH","IE0009355771.USD","BK4139","RVMD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674004785","title":"Revolution Medicines Falls on Pancreatic Cancer Drug Data Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2674004785","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674004785?lang=en_us&edition=fundamental","pubTime":"2026-10-09 02:17","pubTimestamp":1791483427,"startTime":"0","endTime":"0","summary":"BUZZ-Revolution Medicines falls on pancreatic cancer drug data concerns** Shares of Revolution MedicinesRVMD.Odown 8.1% at $185.91 in afternoon trading** RBC Capital Markets says stock looks to be dow","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nL4N45U1II:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","RVMD","CANC","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","BK4139","IE0002141913.USD","LU0889565916.HKD","LU0109394709.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","IE0009355771.USD","PTH","IDNA","IE00B2B36J28.USD","IE0009354923.USD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674091230","title":"Revolution trading down after daraxonrasib review docs, says Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2674091230","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674091230?lang=en_us&edition=fundamental","pubTime":"2026-10-09 00:05","pubTimestamp":1791475557,"startTime":"0","endTime":"0","summary":"Stifel says shares of Revolution Medicines (RVMD) are lower after the FDA posted multidisciplinary review documents for daraxonrasib with additiona...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-trading-down-after-daraxonrasib-review-docs-says-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-trading-down-after-daraxonrasib-review-docs-says-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009355771.USD","IE00BJT1NW94.SGD","BK4588","RVMD","BK4585","CANC","IE0009354923.USD","IE00B2B36J28.USD","IE0002141913.USD","BBH","LU0109394709.USD","LU0889565916.HKD","IE00BJJMRZ35.SGD","IDNA","IE00B4R5TH58.HKD","LU0320765992.SGD","LABU","PTH","BK4139","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674009816","title":"Cboe data shows mixed options sentiment in Moderna with shares down 0.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674009816","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674009816?lang=en_us&edition=fundamental","pubTime":"2026-10-08 23:55","pubTimestamp":1791474923,"startTime":"0","endTime":"0","summary":"Cboe data shows mixed options sentiment in Moderna (MRNA), with shares down $1.11 near $195.37. Options volume relatively light with 36k contracts ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cboe-data-shows-mixed-options-sentiment-in-moderna-with-shares-down-0-56-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cboe-data-shows-mixed-options-sentiment-in-moderna-with-shares-down-0-56-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MRNA","BK4585","BK4532","BK4501","BK4533","BK4548","GNOM","LGHT","WDNA","BK4551","BK4568","IDNA","MRNX","BK4534","BK4588","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673077189","title":"CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2673077189","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673077189?lang=en_us&edition=fundamental","pubTime":"2026-10-08 20:30","pubTimestamp":1791462600,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland and BOSTON, Oct.  08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310, its investigational CRISPR/Cas9","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/08/3377269/0/en/crispr-therapeutics-to-present-late-breaking-data-at-the-american-heart-association-aha-scientific-sessions-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861558580.USD","BK4117","LU1861559042.SGD","SYNB","ARKG","AGT","BK4585","AFG","BK4588","BK4556","CRSP","BK4139","BK4107","BK4611","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673074298","title":"Incyte Updates Financial Calendar with Third-Quarter Results Conference Call and Webcast Schedule","url":"https://stock-news.laohu8.com/highlight/detail?id=2673074298","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673074298?lang=en_us&edition=fundamental","pubTime":"2026-10-08 20:01","pubTimestamp":1791460900,"startTime":"0","endTime":"0","summary":"Incyte updates financial calendar with third-quarter results conference call and webcast scheduleIncyte scheduled its Q3 2026 results release for Oct. 29, 2026, at 7:00 a.m. ET.Management will host th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nNDLbL9kYp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","INCY","BK4139","BK4532","BK4585","IDNA","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}